Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-9
- Development stage
- Discontinued
- Lead developer
- Università degli Studi di Firenze
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
PG-9 is a synthetic small molecule research compound that functions as a presynaptic cholinergic modulator. Described in the mid-1990s by researchers at the University of Florence, it was developed as part of a series of tropane-based esters investigated for their ability to enhance acetylcholine release. Pharmacologically, PG-9 has been studied for its potential as a nootropic (cognition enhancer) and analgesic agent, showing activity in preclinical models of memory and pain. Chemically, it is the maleate salt of a brominated phenylpropionic acid ester of a tropane derivative. It is currently utilized primarily as a pharmacological tool in neuroscience research to investigate cholinergic signaling pathways and is not approved for therapeutic use in humans.
Beyond the preview
Go deeper on PG-9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG-9.